Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;63(3):410-414.
doi: 10.2967/jnumed.121.262240. Epub 2021 Jun 24.

177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience

Oliver Sartor  1 , Christian la Fougère  2 , Markus Essler  3 , Samer Ezziddin  4 , Gero Kramer  5 , Jörg Ellinger  6 , Luke Nordquist  7 , John Sylvester  8 , Giovanni Paganelli  9 , Avivit Peer  10 , Martin Bögemann  11 , Jeffrey Meltzer  12 , Per Sandström  12 , Frank Verholen  13 , Daniel Y Song  14
Affiliations

177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience

Oliver Sartor et al. J Nucl Med. 2022 Mar.

Erratum in

  • Errata.
    [No authors listed] [No authors listed] J Nucl Med. 2022 Jul;63(7):100-1000. J Nucl Med. 2022. PMID: 35772958 Free PMC article. No abstract available.

Abstract

We analyzed real-world clinical outcomes of sequential α-/β-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We assessed safety and overall survival in 26 patients who received 177Lu-prostate-specific membrane antigen ligand (177Lu-PSMA) after 223Ra in the ongoing noninterventional REASSURE study (223Ra α-Emitter Agent in Nonintervention Safety Study in mCRPC Population for Long-Term Evaluation; NCT02141438). Results: Patients received 223Ra for a median of 6 injections and subsequent 177Lu-PSMA for a median of 3.5 mo (≥ the fourth therapy in 69%). The median time between 223Ra and 177Lu-PSMA treatment was 8 mo (range, 1-31 mo). Grade 3 hematologic events occurred in 9 of 26 patients (during or after 177Lu-PSMA treatment in 5/9 patients; 8/9 patients had also received docetaxel). Median overall survival was 28.0 mo from the 223Ra start and 13.2 mo from the 177Lu-PSMA start. Conclusion: Although the small sample size precludes definitive conclusions, these preliminary data, especially the 177Lu-PSMA treatment duration, suggest that the use of 177Lu-PSMA after 223Ra is feasible in this real-world setting.

Keywords: 177Lu-prostate-specific membrane antigen; 223Ra; metastatic castration-resistant prostate cancer; real-world evidence; treatment sequence.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
Anticancer therapies administered before 177Lu–PSMA. All patients received 223Ra.
FIGURE 2.
FIGURE 2.
Time since end of 223Ra to start of 177Lu-PSMA ligand and duration of 177Lu-PSMA therapy.
See this image and copyright information in PMC

References

    1. Parker C, Nilsson S, Heinrich D, et al. . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. - PubMed
    1. Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. . A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80:82–94. - PMC - PubMed
    1. Kratochwil C, Fendler WP, Eiber M, et al. . EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–2544. - PubMed
    1. Hofman MS, Emmett L, Sandhu SK, et al. . [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804. - PubMed
    1. Morris MJ, De Bono JS, Chi KN, et al. . Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION) [abstract]. J Clin Oncol. 2021;39(suppl):LBS4.

Associated data